SequelSEC

PETMED EXPRESS INC PETS

Retail-Drug Stores and Proprietary Stores · CIK 0001040130 · Fiscal year ends 0331

Revenue
$179.02M
Fiscal year ended 2026-03-31
Operating income
-$58.67M
Fiscal year ended 2026-03-31
Free cash flow
-$33.01M
Fiscal year ended 2026-03-31

PETMED EXPRESS INC (PETS) reported revenue of $179.02M and net income of -$57.29M for the fiscal year ended 2026-03-31. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from PETMED EXPRESS INC’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Retail-Drug Stores and Proprietary Stores.

Income

PETMED EXPRESS INC income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-03-312025-03-312024-03-312023-03-312022-03-312021-03-312020-03-312019-03-312018-03-312017-03-31
Revenue$179.02M$226.97M$274.10M$247.57M$272.28M$303.58M$284.12M$283.42M$273.80M$249.18M
Cost of revenueUnavailable$157.84M$189.33M$171.07M$195.34M$219.27M$202.88M$188.10M$175.99M$169.86M
Gross profit$50.22M$69.14M$84.77M$76.50M$76.94M$84.32M$81.25M$95.31M$97.81M$79.31M
Operating income-$58.67M-$1.53M-$8.16M$6.05M$24.29M$30.53M$30.98M$46.17M$52.14M$37.48M
Net income-$57.29M-$6.27M-$7.46M$5.14M$18.72M$23.92M$25.85M$37.74M$37.28M$23.82M
Research & developmentUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Weighted-average diluted sharesshares 20.92Mshares 20.60Mshares 20.40Mshares 20.34Mshares 20.36Mshares 20.12Mshares 20.06Mshares 20.49Mshares 20.43Mshares 20.38M
Pretax income-$57.36M-$587.00K-$6.27M$7.44M$24.18M$30.95M$33.89M$49.12M$53.79M$37.92M
Income tax expense-$73.00K$5.68M$1.19M$2.30M$5.47M$7.03M$8.04M$11.38M$16.51M$14.10M
Diluted EPS$-2.74$-0.30$-0.37$0.25$0.92$1.19$1.29$1.84$1.82$1.17
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrative$50.73M$38.65M$55.25M$41.71M$31.11M$29.72M$25.26M$24.77M$24.29M$22.80M
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

PETMED EXPRESS INC balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-03-312025-03-312024-03-312023-03-312022-03-312021-03-312020-03-312019-03-312018-03-312017-03-31
Cash & equivalents$21.41M$54.72M$55.30M$104.09M$111.08M$118.72M$103.76M$100.53M$77.94M$58.73M
Total assets$81.19M$148.70M$169.88M$167.48M$179.70M$187.50M$155.32M$154.43M$134.84M$112.81M
Current assets$43.56M$78.87M$93.65M$130.43M$151.00M$161.19M$129.02M$126.43M$105.24M$81.78M
Total liabilities$52.25M$63.57M$73.15M$57.51M$56.25M$46.22M$25.31M$19.75M$19.10M$19.44M
Current liabilities$52.03M$62.77M$72.16M$57.51M$56.25M$44.94M$24.34M$18.63M$18.11M$18.36M
Total equity incl. NCI$28.94M$85.13M$96.73M$109.97M$123.45M$124.93M$120.34M$134.68M$115.73M$93.37M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Inventory$13.61M$16.20M$28.56MUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivable$1.91M$2.32M$3.28M$1.74M$1.91M$2.59M$3.84M$2.54M$2.29M$1.81M
Goodwill$0$26.66M$26.66M$0UnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payable$20.91M$23.56M$37.02M$25.21M$27.50M$39.55M$19.66M$16.28M$15.27M$15.22M

Cash flow

PETMED EXPRESS INC cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-03-312025-03-312024-03-312023-03-312022-03-312021-03-312020-03-312019-03-312018-03-312017-03-31
Operating cash flow-$28.39M$4.72M$4.32M$27.80M$18.50M$40.08M$38.84M$45.14M$37.38M$47.20M
Capital expenditures$4.62M$5.11M$4.51M$5.26M$1.75M$2.43M$2.31M$620.00K$703.00K$10.60M
Investing cash flow-$4.62M-$5.11M-$40.67M-$10.26M-$1.75M-$2.43M-$2.31M-$620.00K-$703.00K-$10.60M
Financing cash flow-$299.00K-$181.00K-$12.44M-$24.54M-$24.38M-$22.69M-$33.30M-$21.92M-$17.47M-$15.51M
Net change in cash-$33.31M-$576.00K-$48.79M-$6.99M-$7.64M$14.96M$3.23M$22.59M$19.21M$21.09M
Stock-based compensation$1.36M-$6.59M$6.87M$6.62M$4.55M$3.31M$2.82M$3.10M$2.58M$1.94M
Common dividends paid$21.00K$181.00K$12.44M$24.54M$24.38M$22.69M$21.80M$21.92M$17.47M$15.51M
Common share repurchasesUnavailableUnavailableUnavailableUnavailable$0$0$11.50M$0UnavailableUnavailable
Depreciation & amortization$9.39M$7.04M$7.06M$3.55M$2.74MUnavailableUnavailableUnavailableUnavailableUnavailable

Derived

PETMED EXPRESS INC derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-03-312025-03-312024-03-312023-03-312022-03-312021-03-312020-03-312019-03-312018-03-312017-03-31
Free cash flow-$33.01M-$395.00K-$194.00K$22.54M$16.75M$37.64M$36.53M$44.52M$36.68M$36.60M
Gross margin28.1%30.5%30.9%30.9%28.3%27.8%28.6%33.6%35.7%31.8%
Operating margin-32.8%-0.7%-3.0%2.4%8.9%10.1%10.9%16.3%19.0%15.0%
FCF margin-18.4%-0.2%-0.1%9.1%6.2%12.4%12.9%15.7%13.4%14.7%
SBC / revenue0.8%-2.9%2.5%2.7%1.7%1.1%1.0%1.1%0.9%0.8%
Current ratio0.84x1.26x1.30x2.27x2.68x3.59x5.30x6.79x5.81x4.46x
Revenue YoY growth-21.1%-17.2%10.7%-9.1%-10.3%6.8%0.2%3.5%9.9%Unavailable
Net margin-32.0%-2.8%-2.7%2.1%6.9%7.9%9.1%13.3%13.6%9.6%
R&D / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
CapEx / revenue2.6%2.3%1.6%2.1%0.6%0.8%0.8%0.2%0.3%4.3%
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailable31.0%22.6%22.7%23.7%23.2%30.7%37.2%

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open PETS in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-13View SEC filing
10-K · Filed 2026-06-02View SEC filing
10-Q · Filed 2026-02-05View SEC filing
10-Q · Filed 2025-12-19View SEC filing
10-Q · Filed 2025-12-19View SEC filing
10-K · Filed 2025-10-14View SEC filing

Companies in the same industry

Reconciliation checks needing review

2 periods on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.

balance equationreview2021-03-31

Difference 16352000 exceeds tolerance 1000000. Presentation or filing-vintage differences need review.

balance equationreview2020-03-31

Difference 9668000 exceeds tolerance 1000000. Presentation or filing-vintage differences need review.